SCHEMBL13814719

SCHEMBL13814719

Cc1cc(C2CN(C(=O)OC(C)(C)C)CCC2NC(=O)c2ccc(Cl)cc2)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
USP30 Q70CQ3 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC6 Q9UBN7 1/20 0.43
SPTLC2 O15270 5/20 0.42
MEN1 O00255 2/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
STS P08842 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PDE4B Q07343 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
CHRNA7 P36544 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13801612 1.00 KMT2A (0.43) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13801611 0.94 HTR3E (0.44) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13814603 0.94 HTR3E (0.44) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13814678 0.93 TACR2 (0.45) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13801614 0.93 TACR2 (0.45) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13801636 0.93 TACR2 (0.45) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13801256 0.93 TACR2 (0.45) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13814586 0.93 TACR2 (0.45) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13801288 0.90 TACR3 (0.48) KMT2AUSP30HDAC4HDAC6SPTLC2
SCHEMBL13814659 0.90 TACR3 (0.48) KMT2AUSP30HDAC4HDAC6SPTLC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT KMT2A 977/4885USP30 3991/4885HDAC4 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.